BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 23900738)

  • 1. Lung cancer stem cells: a biological and clinical perspective.
    Koren A; Motaln H; Cufer T
    Cell Oncol (Dordr); 2013 Jul; 36(4):265-75. PubMed ID: 23900738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.
    Tirino V; Camerlingo R; Bifulco K; Irollo E; Montella R; Paino F; Sessa G; Carriero MV; Normanno N; Rocco G; Pirozzi G
    Cell Death Dis; 2013 May; 4(5):e620. PubMed ID: 23640462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.
    Zhou X; Li D; Wang X; Zhang B; Zhu H; Zhao J
    Oncotarget; 2015 Feb; 6(5):3111-22. PubMed ID: 25605013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cells in lung cancer: Evidence and controversies.
    Alamgeer M; Peacock CD; Matsui W; Ganju V; Watkins DN
    Respirology; 2013 Jul; 18(5):757-64. PubMed ID: 23586700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer effects of cinnamic acid in lung adenocarcinoma cell line h1299-derived stem-like cells.
    Huang Y; Zeng F; Xu L; Zhou J; Liu X; Le H
    Oncol Res; 2013; 20(11):499-507. PubMed ID: 24063280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
    Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
    Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p.
    Wang L; Yang G; Zhao D; Wang J; Bai Y; Peng Q; Wang H; Fang R; Chen G; Wang Z; Wang K; Li G; Yang Y; Wang Z; Guo P; Peng L; Hou D; Xu W
    Mol Cancer; 2019 Apr; 18(1):86. PubMed ID: 30975145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    Bidlingmaier S; Zhu X; Liu B
    J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
    Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
    Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
    Roudi R; Korourian A; Shariftabrizi A; Madjd Z
    Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy.
    Mirza S; Jain N; Rawal R
    Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
    Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G
    Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
    Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
    Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
    Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.